Loading clinical trials...

Evaluate the Safety and Efficacy of Intrathecal Injection of RJK002 in Patients With Amyotrophic Lateral Sclerosis | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITINGPHASE1

Evaluate the Safety and Efficacy of Intrathecal Injection of RJK002 in Patients With Amyotrophic Lateral Sclerosis

A Single-arm, Open-label, Phase I Clinical Study to Evaluate the Safety and Efficacy of a Single Intrathecal Injection of RJK002 in Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT06493279•RJK Biopharma Ltd

View on ClinicalTrials.gov

Summary

The goal of the study aims to evaluate the safety and tolerability of a single intrathecal injection of RJK002 in subjects with amyotrophic lateral sclerosis (ALS), and to determine the recommended Phase II dose (RP2D).

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Female or male subjects who are ≥ 18 years of age at screening;
•2. Patients with a diagnosis consistent with clinically or laboratory-supported possible, probable, or definite sporadic or familial ALSALS in accordance with Revised EI Escorial diagnostic criteria published by the World Federation of Neurology (WFN);
•3. The duration of the disease from the first symptom (any ALS symptom) prior to the screening visit must be less than 2 years (inclusive);
•4. The Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) score ≥30 during the screening period, and the three respiratory scores (dyspnea, upright respiration, and respiratory insufficiency) must be ≥3;
•5. The forced vital capacity (FVC) of predicted during the screening period is ≥70% at screening;
•6. Body mass index (BMI) greater than 18 kg/m2 at screening;

Exclusion Criteria

•1. Subjects with other neurological diseases similar to ALS that affect the evaluation of drug efficacy, such as cervical spondylotic myelopathy, syringomyelia, spinal cord and brain stem tumors, hirayama disease, multifocal motor neuropathy, multiple sclerosis, Guillain-Barre syndrome, Parkinson's disease and dementia;
•2. Patients with a diagnosis consistent with clinically or laboratory-supported possible, probable, or definite sporadic or familial ALSALS in accordance with Revised EI Escorial diagnostic criteria published by the World Federation of Neurology (WFN);
•3. Subjects who refuse to take food and medication by nasal feeding tube during the study period due to swallowing dysfunction;

Locations (1)

Peking University Third Hospital

Beijing, China

Key Dates

Start Date

September 24, 2024

Primary Completion Date

November 30, 2026

Completion Date

November 30, 2030

Last Updated

November 20, 2025

Enrollment

ESTIMATED participants

Conditions

Amyotrophic Lateral Sclerosis Als

Interventions

RJK002 Intrathecal injection

DRUG